Latest Articles

Publication Date
Detection of Activin A and Follistatin as Potential Biomarkers in Women with Ovarian Endometriosis.

Endometriosis is a condition characterized by the growth of tissue similar to the uterine lining outside the uterus. This study aimed to evaluate certain sex hormones and determine the levels …

Published: April 24, 2026, midnight
The Hidden Epidemic: Why Millions of Women Live with Undiagnosed or Mismanaged Hormone Disorders - inkl

The Hidden Epidemic: Why Millions of Women Live with Undiagnosed or Mismanaged Hormone Disorders inkl

Published: April 23, 2026, 7:26 p.m.
Eutopic echoes ectopic: organoid-based evidence of shared hormone dysregulation in endometriosis.

Published: April 23, 2026, midnight
Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Endometriosis-Associated Pain: A Systematic Review and Meta-Analysis.

To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists versus placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.

Published: April 21, 2026, midnight
Extracellular Matrix Remodeling and Matrix Metalloproteinases in Ovarian Function and Infertility.

Ovarian function relies on a network of well-coordinated molecular mechanisms that regulate follicular development, oocyte maturation, ovulation, and corpus luteum function. When these processes are disrupted, infertility can result. Extracellular …

Published: April 19, 2026, midnight
The impact of endocrine-disrupting chemicals on uterine diseases.

Endocrine-disrupting chemicals (EDCs) are a global concern for human health and the environment. EDCs include plasticizers, pharmaceutical agents, industrial chemicals, fungicides, and pesticides. Thus, EDC exposure is a manmade consequence …

Published: April 17, 2026, midnight
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - The Manila Times

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression The Manila Times

Published: April 15, 2026, 11:45 a.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - GlobeNewswire

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression GlobeNewswire

Published: April 15, 2026, 11:30 a.m.
The efficacy of ultrasound-guided treatment of ovarian endometriosis cysts: A meta-analysis.

The purpose of this meta-analysis was to systematically assess the efficacy of ultrasound-guided therapy of ovarian endometriosis cyst (OEC). Several databases were searched to gather published studies on the efficacy …

Published: April 15, 2026, midnight
A novel magnetic resonance imaging index to evaluate ovarian reserve in endometrioma patients: the ovary to endometrioma volume index.

Ovarian endometrioma is a common form of endometriosis associated with chronic pelvic pain, infertility, and diminished ovarian reserve. Although anti-Müllerian hormone (AMH) is widely used to evaluate ovarian reserve, it …

Published: April 14, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!